Genelux (GNLX) Competitors $2.64 -0.11 (-4.00%) As of 12:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. AUTL, KMDA, VERV, ORKA, ABVX, RVNC, SANA, FULC, RAPP, and ATAIShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Autolus Therapeutics (AUTL), Kamada (KMDA), Verve Therapeutics (VERV), Oruka Therapeutics (ORKA), ABIVAX Société Anonyme (ABVX), Revance Therapeutics (RVNC), Sana Biotechnology (SANA), Fulcrum Therapeutics (FULC), Rapport Therapeutics (RAPP), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Autolus Therapeutics Kamada Verve Therapeutics Oruka Therapeutics ABIVAX Société Anonyme Revance Therapeutics Sana Biotechnology Fulcrum Therapeutics Rapport Therapeutics Atai Life Sciences Autolus Therapeutics (NASDAQ:AUTL) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability. Which has more risk and volatility, AUTL or GNLX? Autolus Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Genelux has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500. Which has stronger valuation & earnings, AUTL or GNLX? Genelux has lower revenue, but higher earnings than Autolus Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$9.01M45.19-$208.38M-$0.88-1.74Genelux$8K12,971.41-$28.30M-$0.88-3.13 Do insiders & institutionals have more ownership in AUTL or GNLX? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 9.3% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to AUTL or GNLX? In the previous week, Autolus Therapeutics had 5 more articles in the media than Genelux. MarketBeat recorded 5 mentions for Autolus Therapeutics and 0 mentions for Genelux. Autolus Therapeutics' average media sentiment score of 0.63 beat Genelux's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Autolus Therapeutics Positive Genelux Neutral Does the MarketBeat Community believe in AUTL or GNLX? Autolus Therapeutics received 213 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 68.25% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% GeneluxOutperform Votes17100.00% Underperform VotesNo Votes Do analysts rate AUTL or GNLX? Autolus Therapeutics currently has a consensus target price of $9.32, indicating a potential upside of 509.15%. Genelux has a consensus target price of $17.75, indicating a potential upside of 545.45%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Autolus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is AUTL or GNLX more profitable? Autolus Therapeutics' return on equity of -63.65% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% Genelux N/A -105.05%-80.16% SummaryAutolus Therapeutics beats Genelux on 11 of the 17 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.49M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-2.899.1426.7920.05Price / Sales12,971.41255.59395.67116.44Price / CashN/A65.8538.2534.62Price / Book3.776.546.864.61Net Income-$28.30M$143.51M$3.22B$248.19M7 Day Performance14.58%5.60%6.80%2.97%1 Month Performance1.85%10.06%13.69%16.58%1 Year Performance-45.22%-0.86%18.25%8.16% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.1319 of 5 stars$2.64-4.0%$17.75+572.3%-36.0%$100.38M$8,000.00-2.8010AUTLAutolus Therapeutics3.2733 of 5 stars$1.48+11.3%$9.32+529.7%-61.9%$393.89M$9.01M-1.22330High Trading VolumeKMDAKamada3.9871 of 5 stars$6.82-1.7%$14.67+115.1%+26.8%$392.01M$160.95M24.36360Earnings ReportAnalyst RevisionVERVVerve Therapeutics3.5594 of 5 stars$4.37-5.6%$25.75+489.2%-22.5%$389.56M$59.61M-1.78110Trending NewsEarnings ReportAnalyst RevisionGap DownORKAOruka Therapeutics2.6327 of 5 stars$10.31+2.5%$39.86+286.6%N/A$386.02MN/A-1.65N/ANews CoverageEarnings ReportAnalyst RevisionABVXABIVAX Société Anonyme2.6387 of 5 stars$5.88-2.2%$34.00+478.2%-58.1%$381.15MN/A0.0061Positive NewsRVNCRevance Therapeutics1.9451 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500Analyst ForecastSANASana Biotechnology2.4868 of 5 stars$1.68-3.7%$10.80+542.9%-75.8%$378.80MN/A-1.20380FULCFulcrum Therapeutics0.7716 of 5 stars$6.93+0.7%$4.50-35.1%-15.5%$374.07M$80M-22.35100Positive NewsRAPPRapport Therapeutics1.8071 of 5 stars$10.19+2.3%$32.67+220.6%N/A$371.92MN/A-2.95N/APositive NewsATAIAtai Life Sciences2.3801 of 5 stars$1.84+11.5%$10.50+470.7%+18.5%$367.62M$308,000.00-2.2780News CoverageEarnings ReportAnalyst ForecastGap Down Related Companies and Tools Related Companies Autolus Therapeutics Alternatives Kamada Alternatives Verve Therapeutics Alternatives Oruka Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Revance Therapeutics Alternatives Sana Biotechnology Alternatives Fulcrum Therapeutics Alternatives Rapport Therapeutics Alternatives Atai Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNLX Stock Free GNLX Stock Alerts